Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.
Roche, Herzog&De MeuronObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
British PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.
German-Portuguese biotech start-up MicroHarvest GmbH and a Munich-based pet food manufacturer want to launch the first dog snack made by single cell protein.
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.
Swiss antibody specialist Memo Therapeutics AG has added CHF20m to its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
More than 900 experts from clusters and the EU Commission discussed at the sold-out 9th European Cluster Conference what cluster policy is needed to make Europe a world leader in prioritised technology fields such as the green and digital transitions and biotechnology.